On August 8, 2025, Assembly Biosciences announced interim results from its Phase 1b study of ABI-5366, showing a 94% reduction in HSV-2 shedding and genital lesions compared to placebo, indicating strong antiviral activity and good tolerance at doses up to 350 mg weekly.